David Hafler
Neurology · New Haven, CTNPI 1689602054
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $74,669 of the $117,711 with a category attached, or 63.4%. 19 manufacturers reported payments, led by Sanofi US Services Inc. at 24.1% of the total. Reporting peaked in 2019 at $41,541 and has fallen 73.1% since, to $11,171 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $1307.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$28K
- Takeda Pharmaceutical Company, Limited$18K
- E.r. Squibb & Sons, L.L.C.$18K
- Biogen$10K
- Bristol Myers Squibb$10K
- Sanofi$8K
- plus $26K from 13 others
Across 46 payments — averaging $72,846 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1.9M
- Genentech, Inc.$574K
- E.r. Squibb & Sons, L.L.C.$459K
- Sanofi$233K
- Sanofi US Services Inc.$160K
What the payments were for
- Consulting fees$74,66963%
- Speaking & faculty fees$8,0127%
- Travel & lodging$30,79526%
- Food & beverage$4,2364%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 10 | $28,312 |
| Takeda Pharmaceutical Company, Limited | 4 | $17,906 |
| E.r. Squibb & Sons, L.L.C. | 8 | $17,667 |
| Biogen | 4 | $9,807 |
| Bristol Myers Squibb | 1 | $9,792 |
| Sanofi | 7 | $7,860 |
| F. Hoffmann-la Roche AG | 14 | $6,646 |
| Sanofi-aventis U.S. LLC | 6 | $6,165 |
| Genentech USA, Inc. | 6 | $5,080 |
| EMD Serono, Inc. | 7 | $2,408 |
| Merck | 1 | $2,093 |
| GSK | 1 | $1,754 |
| Neurocrine Biosciences, Inc. | 7 | $698 |
| Genentech, Inc. | 4 | $505 |
| Novartis | 4 | $376 |
| TG Therapeutics, Inc. | 2 | $232 |
| AstraZeneca | 2 | $162 |
| Regeneron | 1 | $125 |
| CSL Behring | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$16,897
- OCREVUS$2,782
- Non-Covered Product$2,007
- BRIUMVI$232
- KESIMPTA$228
- ULTOMIRIS$132
- AUBAGIO$125
- Hizentra$125
How this compares
$117,711 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.
Other neurology in New Haven
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Stephen WaxmanNew Haven$252K
- Ariel LeflandNew Haven$220K
- David RussellNew Haven$208K
- Richard NowakNew Haven$126K
- Kenneth MarekNew Haven$86K
- Daniel DicapuaNew Haven$85K
- Lee SchwammNew Haven$55K
- Marcelo MatielloNew Haven$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.